Cogent Biosciences, Inc. Convertible Preferred Stock Converted to Other Securities
Cogent Biosciences, Inc. (COGT) reported Convertible Preferred Stock Converted to Other Securities of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities · last filed 2024-05-07
- Cogent Biosciences, Inc. convertible preferred stock converted to other securities for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Cogent Biosciences, Inc. convertible preferred stock converted to other securities for the quarter ending 2023-12-31 was $0.00.
- Cogent Biosciences, Inc. convertible preferred stock converted to other securities for the quarter ending 2023-09-30 was $2.27M, a 59.16% decline year-over-year.
- Cogent Biosciences, Inc. convertible preferred stock converted to other securities for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Cogent Biosciences, Inc. convertible preferred stock converted to other securities for fiscal 2023 was $5.79M, a 70.39% decline from fiscal 2022.
- Cogent Biosciences, Inc. convertible preferred stock converted to other securities for fiscal 2022 was $19.57M, a 23.20% decline from fiscal 2021.
- Cogent Biosciences, Inc. convertible preferred stock converted to other securities for fiscal 2021 was $25.48M, a 6.84% decline from fiscal 2020.
- Cogent Biosciences, Inc. convertible preferred stock converted to other securities for fiscal 2020 was $27.35M.
| Period end | Convertible Preferred Stock Converted to Other Securities 3 month | Convertible Preferred Stock Converted to Other Securities 6 month | Convertible Preferred Stock Converted to Other Securities 9 month | Convertible Preferred Stock Converted to Other Securities 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2024-05-07 | $2.27M derived: sum of 3 quarters · filed 2024-05-07 | $2.27M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $2.27M derived: sum of 2 quarters · filed 2024-02-26 | $2.27M derived: sum of 3 quarters · filed 2024-02-26 | $5.79M 10-K · filed 2024-02-26 |
| 2023-09-30 | $2.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.27M derived: sum of 2 quarters · filed 2023-11-07 | $5.79M 10-Q · filed 2023-11-07 | $5.79M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.52M 10-Q · filed 2023-08-08 | $3.52M derived: sum of 3 quarters · filed 2024-05-07 | $9.09M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | $3.52M 10-Q · filed 2024-05-07 | $3.52M derived: sum of 2 quarters · filed 2024-05-07 | $9.09M derived: sum of 3 quarters · filed 2024-05-07 | $16.09M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $5.57M derived: sum of 2 quarters · filed 2024-02-26 | $12.57M derived: sum of 3 quarters · filed 2024-02-26 | $19.57M 10-K · filed 2024-02-26 |
| 2022-09-30 | $5.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $12.57M derived: sum of 2 quarters · filed 2023-11-07 | $19.57M 10-Q · filed 2023-11-07 | $19.57M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $14.00M 10-Q · filed 2023-08-08 | $14.00M derived: sum of 3 quarters · filed 2024-02-26 | $14.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $7.00M 10-Q · filed 2023-05-09 | $7.00M derived: sum of 2 quarters · filed 2024-02-26 | $7.00M derived: sum of 3 quarters · filed 2024-02-26 | $16.28M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $9.28M derived: sum of 3 quarters · filed 2024-02-26 | $25.48M 10-K · filed 2024-02-26 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $9.28M derived: sum of 2 quarters · filed 2022-11-14 | $25.48M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $9.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $25.48M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $16.20M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $27.35M 10-K · filed 2022-03-15 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$13.00K derived: sum of 2 quarters · filed 2020-03-26 | $77.15M 10-K · filed 2020-03-26 | |
| 2018-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $77.15M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $77.17M 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |